Guanine nucleotides protect against kainate toxicity in an ex vivo chick retinal preparation  by Burgos, Javier S et al.
Guanine nucleotides protect against kainate toxicity in an ex vivo chick
retinal preparation
Javier S. Burgosa, Ana Barata, Diogo O. Souzab, Galo Ram|Łreza;*
aCentro de Biolog|Ła Molecular (CSIC-UAM), Universidad AutoŁnoma, Canto Blanco, 28049 Madrid, Spain
bDepartamento de Bioqu|Łmica, Instituto de CieŒncias BaŁsicas da SauŁde, Universidade Federal do Rio Grande do Sul,
Porto Alegre, RS 90035-003, Brazil
Received 28 April 1998
Abstract Ex vivo preparations of chick neural retina have been
successfully used in the assessment of excitotoxicity and in the
evaluation of the protective effects of glutamate antagonists.
Using a variation of this approach, and measuring the acute and
delayed toxic effects of kainate (KA) in terms of lactate
dehydrogenase release, we have shown that guanine nucleotides
behave as effective neuroprotecting agents. The anti-excitotoxic
potency of guanine nucleotides (in the case of GMP and GDPLS
it is about 100 times lower than that of DNQX, a powerful
kainate antagonist) correlates well with their ability to displace
KA from retinal KA receptors.
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1. Introduction
The interaction of guanine nucleotides (GNs) with excita-
tory amino acid receptors, at the extracellular level, is already
a well-established fact: both the common native nucleotides,
GTP, GDP and GMP, and the non-hydrolyzable, synthetic
analogs have been shown to displace agonists (and, in some
cases, antagonists) from both ionotropic receptors, including
NMDA [1^3] and non-NMDA [4^6] types, and metabotropic
receptors [7,8]. The structural basis for this phenomenon has
been at least partially elucidated [5,7,9], although some con-
tradictions concerning the mechanisms of competition be-
tween amino acid agonists and GNs remain to be explained
[10].
Unequivocal neuroprotective e¡ects have furthermore been
demonstrated for GMP in characteristic neurotoxicity exper-
imental paradigms, both in vivo [11] and in tissue slices [12].
The need for a simple system to test the validity and the
relative potency of di¡erent GN analogs and derivatives as
neuroprotectors has prompted us to explore the suitability
of the chick retina as a model to analyze the ability of GNs
to antagonize the toxic actions of excitatory amino acids.
Although early descriptions of the deleterious e¡ects of gluta-
mate on the mouse retina [13] were based on the parenteral
administration of the amino acid (see [14] for a discussion),
the use of the ex vivo chick (or mouse) retinal preparation for
excitotoxicity analysis was later successfully adopted in several
laboratories [15^21]. We have taken advantage of a further
adaptation of this retinal model to set up a simple and sensi-
tive system to evaluate the neuroprotective e¡ects of GNs and
other EAA antagonists on the acute and delayed e¡ects of a
single dose of kainate. Our results con¢rm once again the
striking neuroprotective e¡ect of some guanine nucleotides,
especially 5P-GMP, and may contribute to ¢nding practical
applications of this interaction between GNs and EAA recep-
tors.
2. Materials and methods
2.1. Animals
White Leghorn chick (Gallus domesticus) embryos of the desired
developmental stage were produced by incubation of fertile eggs, in
our own facilities, using a forced-draft incubator, with controlled
temperature and humidity, and automatic turning.
2.2. Chemicals
[3H]Kainic acid (58 Ci/mmol) was obtained from New England
Nuclear, Germany, and purine nucleotides and DNQX from Sigma.
All other chemicals were from standard commercial suppliers.
2.3. Dissection of neural retinas and experimental setup
All operations were carried out at room temperature. Thirteen-day
chick embryos (13 þ 1) were used for easy separation of the neural
retina from the pigment/vascular layer. After decapitation and eye
removal the eyecups were placed in a Krebs-like balanced salt solution
(KBSS) containing 119 mM NaCl, 4.6 mM KCl, 2.5 mM CaCl2, 1.2
mM MgSO4, 1.2 mM KH2PO4, and 24.9 mM NaHCO3, adjusted to
pH 7.4 with 95% O2/5% CO2 [21]. The eyecups were kept in the dark
until dissection. After excision of the cornea and the lens, the vitreous
humor was gently pulled out and then the retina was removed as a
continuous sheet and placed, inside a small plastic container ¢tted
with a nylon mesh at the bottom, in one of the wells of a 24-well
tissue culture plate ¢lled with KBSS. This arrangement facilitates the
sequential exposure of the retina to di¡erent solutions with a mini-
mum of manipulation.
2.4. Characterization of binding sites for [3H]KA in chick neural retina
membranes
E13 embryonic neural retinas, dissected as above, but working al-
ways at 4‡C, were homogenized, in 20 volumes of distilled water, in a
Polytron homogenizer (setting 5; 15 s), and then rehomogenized in a
Dounce glass-glass homogenizer (Kontes). The suspension was centri-
fuged at 100 000Ug for 30 min and the pellet was resuspended in
water and subjected to two additional cycles of Polytron/Dounce ho-
mogenization. The ¢nal pellet was resuspended in 1 mM Tris-HCl, pH
7.4, and used for binding experiments.
Binding was carried out as previously described [4,10], using
[3H]KA of high speci¢c radioactivity. KA concentrations for satura-
tion experiments ranged from 2 to 1000 nM, whereas 40 nM was used
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in displacement experiments. Non-speci¢c binding was estimated in
the presence of 0.4 mM non-labeled KA. Displacing antagonists, at
concentrations between 4 nM and 4 mM were added 10 min before
[3H]KA.
2.5. Exposure of chick embryo retinas to di¡erent substances
Within 15 min after dissection, the containers with the neural ret-
inas were transferred to wells containing, in 1 ml of KBSS at room
temperature, kainate, kainate-receptor antagonists and/or nucleotides,
in di¡erent combinations and at di¡erent concentrations (see Section
3). In neuroprotection assays, pre-incubation with antagonists and
nucleotides was routinely carried out for 10 min before addition of
kainate. After 1 h of exposure to kainate the retinas were thoroughly
washed by sequential immersion in wells with KBSS, and then incu-
bated for an additional hour (or longer) in KBSS without kainate. All
retinas were frozen at the end of the experiment.
2.6. LDH assays
The acute and delayed toxicity of kainate was assessed by measur-
ing the liberation of LDH into the incubation medium. In routine
experiments LDH was measured independently in the two 1-ml ex-
perimental medium aliquots (¢rst and second hours) and in the ¢rst of
the three intermediate washes. LDH was estimated spectrophotomet-
rically by measuring the rate of disappearance of NADH (at 340 nm)
in a 1-ml solution containing 0.2 ml of the sample in 50 mM Tris-HCl,
pH 7.2, 1.2 mM Na-pyruvate, and 0.15 mM NADH (¢nal concen-
trations) [22]. The frozen retinas were thawed the next day and as-
sayed also for LDH. LDH released by kainate was expressed as per-
cent of the total LDH in the retina. Control retinas, exposed only to
KBSS, were carried along in parallel to assess the degradative e¡ects
of the dissection and incubation procedures. These control values
were always subtracted from experimental values in the same batch
of retinas.
3. Results
3.1. Binding sites for [3H]kainate in chick retinal membranes
To compare the e⁄ciency of prospective glutamate antago-
nists (including GNs), both as displacers in conventional bind-
ing experiments and as neuroprotective agents, we carried out
a partial characterization of KA-binding sites in a preparation
of embryonic chick neural retinal membranes (E13). As seen
in Fig. 1, binding data can be adjusted to a two-site model
with Kds of 4 and about 200 nM. This distribution of appar-
ent a⁄nities agrees well with the original paper of Biziere and
Coyle [23] except for some quantitative di¡erences in the Bmax
probably related to their using a di¡erent membrane prepara-
tion and a radioactive KA of much lower speci¢c radioactiv-
ity. Routine displacement experiments for screening purposes
were carried out at a 40 nM concentration of [3H]KA.
3.2. Optimization of the experimental procedure to assess
excitotoxicity
Two hundred and eighty-three chick embryonic retinas were
independently processed for the neurotoxicity/neuroprotection
experiments. The average LDH activity per retina was
25.2 þ 2.2 OD340 units/min. After 1 h of exposure to 0.1
mM kainate, LDH activity in the medium was over 10 times
that of the control without kainate (Fig. 2). Washing the
treated retinas with KBSS did not stop the leakage of LDH
upon incubation in fresh aliquots of KBSS. However, longer
incubations also resulted in progressively higher readings in
the control retinas. Incidentally, this continued (delayed) re-
lease of LDH after removal of the toxin was not inhibited by
inclusion of either non-NMDA or NMDA receptor antago-
nists (1 mM DNQX, MK-801 or AP7), suggesting that it was
not due to traces of kainate, or to depolarization-induced
release of glutamate, but to irreversible damage of the cell
upon the initial exposure to KA. For routine experiments
we therefore settled for 1 h of exposure to the excitotoxin
plus one additional hour to collect LDH in the absence of
KA. In Fig. 2 this accounts for 62% of the total LDH released
in the 4-h period, and the KA-speci¢c/control ratio is still
higher than 5 (corresponding to a highly signi¢cant di¡erence
between the KA-speci¢c and control LDH values: P6 0.0001
in Student’s paired t-test). Using this acute/delayed 2-h pro-
tocol, exposure to 0.1 mM kainate produced a KA-speci¢c
LDH release of 3.6 þ 0.7% (mean þ S.D. of 47 determinations,
after deduction of control (blank) values) of the total retinal
LDH whereas spontaneous release in controls was 0.7 þ 0.3%
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Fig. 1. Saturation analysis of [3H]KA speci¢c binding sites in chick
embryonic neural retina (E13): Eadie-Scatchard plot of binding
data and adjustment to two discrete populations of binding sites
(SigmaPlot).
Fig. 2. Cumulative release of LDH after exposure of chick neural
retina explants to 0.1 mM KA for 1 h. E13 embryonic chick neural
retinas were dissected, and incubated in the presence of 0.1 mM
KA, as described in Section 2. They were then transferred to fresh
medium without KA and incubated for three additional 1-h periods,
with hourly changes of medium. LDH was measured in the four
consecutive medium aliquots and expressed as percent of the total
retinal LDH (see text). Control retinas, not exposed to KA, were
carried along to determine the e¡ect of spontaneous cell damage.
Values in the graph are mean þ S.D. for six determinations; a, ac-
cumulated total LDH measured in retinas exposed to KA; E, con-
trol retinas; b, speci¢c KA-induced release of LDH (di¡erence be-
tween total and control); R, KA-speci¢c/control LDH ratio.
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(32 determinations). The rates of release of LDH during the
¢rst and second hours were nearly identical, and so were the
protective e¡ects of antagonists. Then, although LDH was
systematically measured after each 1-h period, both readings
were routinely added and considered the total toxic e¡ect.
The dependence of the retinal damage on the concentration
of KA, using this standard protocol, is illustrated in Fig. 3.
The sigmoidal pro¢le of the curve is compatible with the
notion of a receptor-dependent, saturable phenomenon, typi-
cal of EAA-mediated excitotoxicity [24]. The EC50 in Fig. 3,
0.056 mM, is of the same order of magnitude as the KA
concentration used routinely (0.1 mM), which produces a suf-
¢ciently high level of toxicity but can still be overcome by
reasonable concentrations of the antagonists.
The high-slope region of the curve occurs between 1035 and
1033 M KA, which would suggest the preferential involve-
ment of the low-a⁄nity receptors in the excitotoxic action
of KA (see Fig. 1), although due allowance has to be made
for the di¡erence in accessibility of the KA receptors in the
washed, fragmented membrane preparation and in the retinal
explant.
3.3. Neuroprotection experiments
The presumptive neuroprotective drugs were ¢rst tested at a
single 10 mM concentration (100 times the KA concentration)
and a dose-dependence protection curve was further carried
out when the preliminary experiments were positive. The pro-
tection curves for GppNHp, GDPLS and GMP are shown
together in Fig. 4. Besides the evident neuroprotective e¡ect
of all three GNs, the GppNHp pro¢le suggests that this GTP
analog may be acting as a partial agonist or co-agonist, add-
ing to the toxicity of KA at low concentrations and displacing
it at higher concentrations (GppNHp is not toxic when used
alone). PC50s for di¡erent nucleotides (de¢ned as the concen-
tration that a¡ords a 50% protection level) are given in Table
1 and compared with the protective e⁄ciency of DNQX, a
strong and speci¢c antagonist of the AMPA/KA receptors.
The ability of other types of purine nucleotides to counteract
the toxicity of KA has also been explored: whereas the ino-
sine series has about 10% of the protective activity of GNs,
adenine nucleotides appear to have no measurable e¡ect up to
0.01 M.
Since the neuroprotective e¡ect of GNs must be related to
their ability to displace KA from the speci¢c retinal receptors,
we also carried out a series of displacement experiments and
calculated the IC50s for the same nucleotides used in the pro-
tection experiments. As can be seen in Table 1, there is a fair
degree of correspondence between the relative e⁄ciency of
most nucleotides as displacers and neuroprotectors. The
most active in both tests are GMP and GDPLS, which are




Protection by DNQX and di¡erent nucleotides against the toxicity
of a 0.1 mM dose of kainate in 13-day embryonic chick retina






5P-IDP 4.0U1033 s 1032
5P-IMP 2.8U1033 7.6U1033
5P-AppNHp s 1032 s 1032
5P-ADPLS s 1032 s 1032
5P-AMP s 1032 s 1032
Protection curves (see Fig. 4) were carried out for DNQX and the
di¡erent series of purine nucleotides featured in the table, and PC50s
(PC50 : concentration of neuroprotective drug that reduces LDH re-
lease by half) were calculated from the curves. Standard IC50s were
obtained from displacement experiments, in retinal membranes of the
same age, using 40 nM [3H]KA against di¡erent concentrations of
DNQX or nucleotides.
Fig. 3. Percent of retinal LDH released after exposure to di¡erent
concentrations of KA. Chick embryonic retinas were exposed for 1 h
to KA and further incubated in KBSS without KA for one addi-
tional hour. LDH released during this 2-h period, expressed as per-
cent of total retinal LDH (see text), has been plotted against KA
concentration. Values are mean þ S.D. for six independent experi-
ments. The 50% release concentration was estimated as 0.056 mM.
Fig. 4. Protection by GNs against KA toxicity in embryonic chick
neural retina. Retinas were exposed for 1 h to 0.1 mM KA, with or
without GNs, at the concentrations given, and further incubated in
KBSS without KA for one additional hour (GNs were routinely
added 10 min before KA). LDH released at di¡erent concentrations
of GNs, expressed as percent of the enzyme released by KA in the
absence of GNs, was taken as residual toxicity and plotted against
GN concentration. Exposure to the GNs, without KA, gave LDH
readings indistinguishable from control values using KBSS alone.
P, GppNHp; b, GDPLS; a, GMP. Values are mean þ S.D. for
four independent experiments.
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4. Discussion
As described long ago by Biziere and Coyle [23], and con-
¢rmed by us in the present work, two populations of kainate
receptors can be distinguished in chick retinal membranes by
conventional binding techniques (Fig. 1). Thus retina di¡ers
from other chick brain regions, such as tectum and cerebel-
lum, where only the low-a⁄nity site has been found [10,25].
These receptors would be, in principle, the molecular substrate
for the excitotoxic action of KA in the chick retina, already a
¢rmly established fact [14^21,26,27]. The characteristic sig-
moidal shape of the dose-dependence curve for KA (Fig. 3)
and the protection a¡orded by DNQX (Table 1) are equally
suggestive of the involvement of typical KA receptors in the
observed excitotoxic damage.
Exposure of embryonic chick retinal explants to adequate
concentrations of KA, even for a short time, induces a long-
lasting toxic e¡ect leading to cell damage and membrane dis-
ruption, with release of cytoplasmic contents into the medium,
including the intracellular enzyme LDH which is often used as
a marker of cell damage in such excitotoxic experiments
[19,21]. LDH can be detected in the medium early during
exposure to KA (acute phase), and increases for a long time
after terminating the exposure to the excitotoxin (delayed tox-
icity). It is important to mention that both the acute and
delayed e¡ects of KA in this speci¢c model are exclusively
due to the activation of AMPA/KA receptors, being only
blocked by typical AMPA/KA antagonists ^ and not by the
NMDA antagonists AP7 and/or MK801 ^ when applied to-
gether with KA. Furthermore, the delayed toxic e¡ects, once
the exposure of the retina to the toxin is terminated, are ex-
clusively due to this initial period of exposure: addition of
di¡erent glutamate antagonists, with di¡erent receptor specif-
icities, during the post-KA incubation does not stop further
release of LDH.
The exclusive involvement of AMPA/KA receptors in this
neurotoxicity paradigm is compatible with a role for either
Cl3/Na or Ca2 in the causation of cell damage. Whereas
the involvement of Cl3 and Na in the acute phase seems to
be established [16,18], the hypothetical participation of Ca2
ions in the acute and/or the delayed phase can be equally
accepted without the need of implicating NMDA receptors
since AMPA/KA receptors associated with Ca2 channels
are expressed in chick retina [20,28].
Our present work describes yet another system where the
toxicity of EAA agonists can be overcome by the simultane-
ous addition of GNs [11,12]. We have, as in previous cases,
used non-hydrolyzable analogs of GTP and GDP to avoid
ambiguous results due to the hydrolysis that takes place
upon incubation with living tissue. The biphasic e¡ect of
GppNHp (Fig. 4) contrasts with the consistent protective be-
havior of GDPLS and GMP but agrees with our previous
experience in other systems, such as the rat striatum where
GTP analogs a¡ord no protection ([11]; our unpublished re-
sults), and rat hippocampal slices where GppNHp, and even
GTP, are downright toxic in a way that can be blocked by
GMP itself [12]. Since GNs appear to bind to part of the
agonist site, di¡erent GNs may have di¡erent e¡ects upon
the subsequent status of the channel itself [5,9,10].
Examination of Table 1 shows that the e⁄ciency of the
antagonist DNQX and of nucleotides as neuroprotectors par-
allels their ability to displace KA, as would be expected for a
receptor-mediated phenomenon. The displacer/agonist ratio at
the IC50, however, is much higher than the protecting agent/
KA ratio at the PC50, suggesting that only partial displace-
ment of KA may be necessary to block toxicity or that a
critical number of receptors must be activated to cause a
substantial release of LDH.
Table 1 also shows that the antagonistic potency of the
GNs is low when compared with the reference antagonist
DNQX. However, the speci¢city of the phenomenon (relative
to other purine nucleotides) and the negligible toxicity of
compounds such as 5P-GMP [11] provide a promising starting
point for the design of derivatives of higher e⁄ciency but still
acceptable toxicity.
In conclusion, we have presented another ¢tting example of
the potential of some guanine nucleotides (preferentially
GMP, altogether) to act as neuroprotecting agents in a num-
ber of animal models in vivo, ex vivo and in tissue slices. The
simplicity and reliability of our chick retinal preparation and
neurotoxicity/protection protocol makes it especially appro-
priate for the screening of glutamate antagonists (the chick
retina is sensitive to NMDA agonists, too), including more
powerful synthetic analogs of the GNs.
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